Filter Results:
(97)
Show Results For
- All HBS Web
(636)
- People (4)
- News (97)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
Show Results For
- All HBS Web
(636)
- People (4)
- News (97)
- Research (426)
- Events (3)
- Multimedia (4)
- Faculty Publications (259)
Sort by
- 01 Jun 2024
- News
Quantum Leap
“This is the first new kind of computer in 75 years,” says John Levy (MBA 1979), CEO of the quantum computing startup SEEQC. “And we’re building it on a chip!” Strolling through his company’s design and testing facility in Elmsford, New York, Levy looks less like a... View Details
- 01 Sep 2023
- News
Research Brief: Making Way for Moonshots
Josh Krieger (Courtesy subject) Josh Krieger (Courtesy subject) Many innovations in modern medicine have come about due to cutting-edge drugs—advances that required both a scientific leap and a willingness to take risks. And while most View Details
Keywords: Jen McFarland Flint
- 22 Feb 2024
- News
Combat-Tested Cancer Coaching
his company so we could move east and get better care for me. And so I'm reading all of this and I'm thinking, I cannot believe the toll that cancer and illness takes on the patient, but also on everybody around them. And it really made... View Details
- 01 Feb 1999
- News
Too Much of a Good Thing?
layoffs and lost revenues, for example - weak companies are artificially supported," he explains. "Other firms won't or can't restructure themselves or exit unprofitable businesses because they are too set in their ways, lack sound... View Details
Keywords: Garry Emmons
- 01 Oct 2001
- News
Guy de Chazal: Changing Focus
putting too much faith in innovative companies with exciting ideas but untried management. "At Morgan Stanley, we're back to basics: We look for young companies that have the advantage of entering a... View Details
Keywords: Deborah Blagg
- 31 Jan 2014
- News
Body, Heal Thyself
BANCEL Throughout 2009 and 2010, Stéphane Bancel (MBA 2000) had received upward of 20 calls from biotech companies asking him to come aboard and lead the company. It made sense. He was a highly recruited CEO successfully running... View Details
- 01 Jun 2023
- News
From Big Pharma to Startup
pharmaceutical giant one day—not creating a company from scratch. But Goble was determined to explore the wide variety of opportunities available to him in his time at HBS, so when he read about a nonprofit... View Details
Keywords: April White
- 01 Oct 2021
- News
From Scholarship to Life-Saving Impact
ending up with huge medical bills we couldn’t pay.” Inspired by this personal experience, Rabah chose to build a career in health care. She studied biology as an undergraduate at Cornell, where she developed a strong interest in drug pricing and View Details
- 01 Dec 1998
- News
Novartis AG Establishes Global Research Fund
Four HBS professors whose international research efforts range from biotechnology in Taiwan to foreign investments in Costa Rica have been named the first Novartis Faculty Fellows. The two-year fellowships, funded by a $2 million gift from the worldwide View Details
Keywords: Anne Kavanagh
- 18 Sep 2014
- News
Room to grow: global expansion in the middle ground
consulting firm Shaldor, documents the specific strategies various companies pursued. As examples, by focusing on a neglected market segment, Netafim became the world leader in drip irrigation technology, while Teva View Details
- 15 Dec 2024
- News
After Ozempic
Back before Ozempic, when Kate Mulroney (MBA 1984) spoke at technical conferences about her work at Novo Nordisk, people often assumed she was talking about Novartis. “I’d have to explain that’s a Swiss company; we’re Danish,” says Mulroney, now head of advanced... View Details
- 01 Dec 1996
- News
New Releases
a competitive factor. In a three-year study of pharmaceutical and biotechnology firms, Pisano shows that the development of distinctive and superior process technologies can lower costs, improve quality, and increase flexibility. He... View Details
- 01 Jan 2002
- News
Raymond V. Gilmartin (MBA '68)
expected to work for a big company like Kodak for my entire career." Arthur D. Little, 1968-76 Becton, Dickinson and Co., 1976-94 Why HBS? "I learned that an engineer whose desk was close to mine at Kodak had been accepted by the School.... View Details
- 20 Jul 2022
- News
Wired to be Inspired
Subscribe on iTunes Subscribe on Spotify More Skydeck episodes Professor Ranjay Gulati, whose research looks at how the most resilient companies approach growth and profitability, chaired the Advanced Management Program at HBS for many... View Details
- 01 Dec 2003
- News
Alumni Luminaries Discuss Careers, Values with HBS Students
was evident in the questions put to a panel composed of this year's winners of the School’s highest honor, the Alumni Achievement Award. These distinguished graduates were selected for their contributions to their companies and... View Details
- 01 Dec 2004
- News
Finding a Balance
Do the rules of business change when a company’s product holds the power of life or death over its customers? That’s a question students must consider when discussing “Cipla,” a case about a $325 million Indian pharmaceutical View Details
- 08 Jun 2021
- News
New Funding for Female Founders
Boost VC, SV Angel, Village Global, and Threshold Ventures, according to the Wall Street Journal. Coravos is co-founder and CEO of the startup, formerly known as Elektra Labs, which helps hospitals and pharmaceutical View Details
- 01 Oct 1998
- News
Playing to Win
in turning losing teams into winners, Louis-Dreyfus has an enviable record of reshaping underperforming companies into formidable competitors. A scion of one of France's most prominent business families, he rejuvenated IMS International,... View Details
Keywords: Garry Emmons
- 01 Mar 2009
- News
A New Approach to Health-Care Reform
patients’ needs. Today’s doctors work in a system where they are rewarded by Medicare and insurance companies for the number and cost of the services they provide rather than by the value of those services in helping patients. In short,... View Details
- 01 Jan 2003
- News
Daniel L. Vasella, M.D.
Ciba-Geigy and Sandoz and now the sixth largest pharmaceutical company in the world-is doing just that. And Gleevec-the first "designer drug" for patients with chronic myeloid leukemia (CML) that targets... View Details